Hiding in Plain Sight: Familial Hypercholesterolemia (FH)

---

Medical Disclaimer: Content on CardioAdvocate.com is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. No physician–patient relationship is created by use of this site. Always consult a qualified healthcare professional for personal medical concerns.

Case Presentations

Patient A: Homozygous FH (HoFH)

Heart attack by age 9? Bypass by age 12? LDL-C 780 mg/dL! How on Earth does that happen?

Having extremely high levels of LDL-C (> 400 mg/dL) since birth, that's how. Familial hypercholesterolemia (FH) results from a genetic defect which impairs the ability of LDL receptors (LDLR) on liver cells from clearing ApoB-containing atherogenic particles (LDL, VLDL, Lp(a)) from the blood. This results in severely elevated circulating levels of these particles in the bloodstream, which is manifested by extremely high levels of LDL-C in a lipid panel.

Patient B: Heterozygous FH (HeFH)

A 42-year-old woman presents to the lipid clinic with LDL-C ~ 250 mg/dL. She proclaims: "I've been told I have really high cholesterol since I was in high school, when they did a health screening. They told me I needed to change my diet and lose weight. I'm a professional dancer and have been eating healthy ever since and nothing seems to change my cholesterol numbers."

Physical exam revealed tendon xanthomas of the hands (Xanthoma, tendon — DermNet NZ; Cutaneous Manifestations in HoFH — AJMS) and corneal arcus of the eyes (Correlating corneal arcus with atherosclerosis in FH — PMC, Arcus Senilis — EyeWiki).

She was referred for genetic testing (often helpful for insurance coverage of advanced lipid therapies) through Ambry Genetics, which confirmed Heterozygous Familial Hypercholesterolemia (HeFH). The news of this genetic condition was emotionally overwhelming for this particular patient, who unfortunately and needlessly, lived her adolescent and adult life feeling her "lack of dietary control and exercise intensity" were to blame for her cholesterol condition.

These patients are not rare. They are hiding in plain sight.

Types of Familial Hypercholesterolemia

Feature	Homozygous FH (HoFH)	Heterozygous FH (HeFH)
LDL-C Level	> 500 mg/dL (up to 1200 mg/dL)	≥ 190 mg/dL (adults); ≥ 160 mg/dL (children)
Prevalence	~1 in 250,000–300,000	~1 in 200–311
Inheritance	Biallelic (two pathogenic variants)	Autosomal semidominant (50% chance of passing)
Genes	LDLR, APOB, PCSK9, LDLRAP1	LDLR (85–90%), APOB (5–15%), PCSK9 (1–3%)
ASCVD Risk	CV events often begin in childhood if untreated	6–22× higher lifetime risk of ASCVD
NonHDL-C Threshold	Severely elevated	> 220 mg/dL (adults); > 190 mg/dL (children)

2026 NLA Update — Terminology: FH is now described as autosomal semidominant rather than "autosomal dominant." The term "codominant" is no longer recommended. Additionally, ICD-10 codes were expanded in 2025 to distinguish HoFH (E78.010), HeFH (E78.011), and FH unspecified (E78.019). The parent code E78.01 is no longer the most specific code to use.

Flying Under the Radar

Is your (or a family member's) LDL-C ≥ 190 mg/dL (adult) or ≥ 160 mg/dL (children)?
If so, this should raise suspicion for FH and warrants further evaluation to rule this out.

Familial hypercholesterolemia is common, genetic, and dangerous — yet remains profoundly underdiagnosed.

According to the 2026 National Lipid Association Expert Clinical Consensus, FH affects approximately 1 in 311 people worldwide, and the majority remain undiagnosed and undertreated. While rare, undiagnosed and untreated patients with HoFH are all but guaranteed a future of recurrent ASCVD events beginning in the pediatric age range.

Much more common, however: patients with undiagnosed and untreated HeFH have a 6–22× higher lifetime risk of having an ASCVD event. And it's easy to screen for and detect.

So How Do These Patients Hide From Us?

With such extremely high cholesterol from birth, how do these patients hide from us? I mean, aren't doctors checking cholesterol levels all the time?

No, sadly they are not. Lipids are frequently not checked in children. Often not in adults either — even when they get admitted to the hospital for a heart attack! Crazy isn't it? But it's true.

It's not uncommon for patients to proclaim: "But I just went to the lab and they took a ton of blood from me. Wasn't my cholesterol checked then?" No, it may not have been.

FH is missed because:

• Elevated LDL-C is often framed as a lifestyle issue rather than a genetic signal
• Standard ASCVD risk calculators significantly underestimate risk and should not be used to guide treatment decisions in FH
• Lipids are not routinely checked in childhood
• Physical findings (xanthomas, arcus) are subtle or unfamiliar to many providers
• Genetic testing is mistakenly viewed as required rather than supportive
• Family history is often incomplete or dismissed
• Women are disproportionately reassured rather than evaluated

Key Concept: FH risk is defined by lifelong cumulative exposure to ApoB-containing particles, not by short-term LDL values. This is why traditional 10-year risk calculators fail in this population.

CardioAdvocate™ Checklist

1. When to Suspect FH

Has LDL-C ever been ≥ 190 mg/dL in adulthood? Was LDL-C ≥ 160 mg/dL in childhood or adolescence? Has "high cholesterol" been present since youth — despite diet and exercise? Is there a family history of premature ASCVD or very high cholesterol?

2. Look Beyond the Lab Value

Examine eyes for corneal arcus and xanthelasma, especially under age 45 Examine/feel backs of hands, Achilles tendons, elbows and knees for tendon xanthomas Have secondary causes been excluded (thyroid, nephrotic syndrome, liver disease)?

3. Diagnosis Without Overcomplication

Use accepted clinical criteria: Dutch Lipid Clinic Network (DLCN) or Simon-Broome Criteria Genetic testing is now Class I (COR 1) for possible/probable/definite FH — 2026 ACC/AHA/NLA Dyslipidemia Guidelines Testing enables cascade screening — critical for identifying at-risk family members

4. Think in Lifetime Risk

Consider LDL burden over time, not just today's value Check lipoprotein(a) at least once — if elevated with FH, a "Double Whammy" of compounded risk Consider coronary artery calcium (CAC) or CCTA to refine near-term risk — but never to delay treatment

5. Avoid the Wrong Tools

Do not use standard ASCVD risk calculators (PCE, PREVENT) — they dramatically underestimate risk in FH Ensure LDL-C goals are aligned with FH-specific targets, not general population targets

6. Get Connected

Refer to a lipid specialist or preventive cardiologist Check ApoB — the preferred biomarker (no fasting required) Cascade screening of first-degree relatives — COR 1 in 2026 ACC/AHA/NLA Guidelines

Questions to Ask Your Clinician

"Could my high cholesterol be genetic rather than dietary?" "Has my nonHDL-C been calculated? What is it?" "Should I get an ApoB test?" "Has my lipoprotein(a) ever been checked?" "Should I be referred to a lipid specialist or preventive cardiologist?" "Should I have genetic testing for familial hypercholesterolemia?" "Should my children or siblings be screened?" "Are we using the correct FH-specific treatment goals — not general population targets?" "If statins alone aren't enough, what are my options for additional LDL-lowering therapy?" "Is my current statin dose appropriate for my actual particle burden?"

Deep Dive

This is a living section — a deeper exploration of the science, evidence, and controversies surrounding familial hypercholesterolemia.

1. FH Awareness: A Measurable Failure

FH is already underrecognized and undertreated. Pharmacotherapy is indicated for those with LDL-C > 190 mg/dL and may be considered for those with LDL-C 160–189 mg/dL, according to all reputable lipid guidelines.

According to a recent NHANES (National Health and Nutrition Examination Survey) report, 2.1% of the US population has an LDL-C > 190 mg/dL, yet more than 1/4 of them (26.8%) were unaware of it or were not on any treatment. This represented 1.4 million Americans.

Healthcare Disparities: "Being unaware and untreated was more common in younger adults, men, racial and ethnic minority groups, those with lower education attainment, those with lower socioeconomic status and those without health insurance." This represents another example of healthcare disparities, to which more awareness campaigns hope to improve.

Key Evidence:
Prevalence, Awareness, and Treatment of Elevated LDL Cholesterol in US Adults, 1999–2020. JAMA Cardiology.

Efforts to combat this lack of awareness has prompted The National Lipid Association and others to advocate CMS to make LDL-C a "Quality Measure," a tool that CMS uses to financially incentivize healthcare systems and providers to adhere to the best evidence-based medicine.

2. Screening Controversy and Policy Failure

It doesn't help when organizations such as the USPSTF recently published an updated guideline claiming there is not sufficient evidence at this time to support routine lipid screening in the pediatric population.

Key Evidence:
Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA.

The NLA and ASPC issued a joint letter to the USPSTF strongly condemning this action, stating:

"This statement was unnecessary and potentially harmful to the population. USPSTF standards require an unreasonable level of evidence to demonstrate the obvious, which is that identification of a common inherited condition with population screening will enable early treatment and prevention of serious outcomes decades later and is superior to the alternative of hopeful screening of adults who already have advanced disease from the untreated condition."

Key Evidence:
NLA/ASPC Response to the USPSTF Recommendation Statement on Screening Lipid Panel in Children and Adolescents. J Clin Lipidol.

The absurdity of the USPSTF recommendations obligates a young child to a shorter lifespan that is spent battling recurrent and otherwise preventable morbidity in the form of devastating ASCVD events.

3. Evidence for Early Treatment

The joint letter further argues the efficacy and safety of treating children with FH in a placebo-controlled statin trial and in a large study by Dr. John Kastelein using registry data from the Netherlands, where screening is universal and covered.

Key Evidence:
Efficacy and Safety of Statin Therapy in Children with Familial Hypercholesterolemia: A Randomized Controlled Trial. JAMA.

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ.

20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. NEJM.

Long-term data from the Dutch registry has now demonstrated that identifying and treating the offspring of FH patients earlier in life resulted in significant delay in the onset of cardiovascular events such as heart attack.

Additional evidence supports that the earlier you identify and treat FH and early atherosclerosis, the more likely we are to prevent disease.

Key Evidence:
Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years. JACC.

Delayed identification guarantees preventable harm. The 2026 NLA Consensus recommends treatment can begin at age 8–10 years, or possibly earlier if there is a family history of very early onset ASCVD events (e.g., age 20–35 years).

4. ASCVD Risk Stratification in FH

ASCVD risk varies among individuals with FH due to multiple factors:

• Underlying genotype
• Severity and duration of exposure to cholesterol and Lp(a)
• Susceptibility of the artery wall to plaque formation
• Concomitant risk factors (diabetes, hypertension, smoking)
• Age at initiation and intensity of LDL-C lowering medications
• Epigenetic factors

🦶 Foot Stomper

Standard risk calculators in FH patients = Class III: Harm. PREVENT and PCE were never designed for genetic hypercholesterolemia. Using them gives false reassurance and delays life-saving treatment. These tools systematically underestimate lifelong risk in FH by 5–10 fold.

2026 ACC/AHA/NLA Dyslipidemia Guidelines (Figure 7: Severe Hypercholesterolemia Algorithm): When LDL-C ≥ 190 mg/dL is identified, the guideline explicitly mandates consideration of FH, genetic testing (now Class I — see below), and cascade screening of first-degree relatives. Standard calculators receive a Class III: Harm recommendation for this population.

2026 ACC/AHA/NLA Dyslipidemia Guidelines, Figure 7

Risk stratification in FH must include a comprehensive clinical assessment, with clinical judgment as the primary guide. Key risk-enhancing factors include:

• Strong family history of early-onset ASCVD
• Elevated Lp(a) — a powerful independent predictor of ASCVD risk in FH
• Presence of subclinical atherosclerosis on imaging (CAC, CCTA)
• Multiple additional CV risk factors

Coronary Artery Calcium Scoring in FH

Given that FH patients have high levels of exposure to atherogenic lipoproteins since birth, the absence of plaque on an imaging study at any one time point should not be used to stop or delay treatment. Moreover, since most plaque is not calcified, the absence of calcified plaque should not be interpreted as "no plaque," particularly in patients with FH.

CAC can be used to further stratify risk and obtain prognostic information, but it should complement — never replace — the decision to treat. See A Picture Worth a Thousand Words — Coronary Artery Calcium.

🦶 Foot Stomper

Genetic testing for FH is now Class I (COR 1). If clinical criteria suggest FH, order the test — it changes management for the patient AND their entire family through cascade screening. The 2026 ACC/AHA/NLA Dyslipidemia Guidelines upgrade genetic testing to Class I evidence for possible, probable, or definite FH, enabling systematic family identification and early preventive treatment.

5. Biomarkers: What Matters

ApoB: The Preferred Biomarker

ApoB may be used as the preferred biomarker for all patients with high TG, diabetes, obesity, metabolic syndrome, or "very low LDL-C" for screening, diagnosis, and risk management (Class Ia, ESC/EAS). No fasting required. Let's repeat that again — No fasting required.

See What's Your ApoB? A Practical Approach to Lipid Biomarkers.

LDL-C: The Primary (but Imperfect) Biomarker

LDL-C is the primary biomarker due to availability, familiarity, and legacy. It's a calculated metric and usually not directly measured.

• A surrogate for LDL particles
• Friedewald equation no longer the preferred way to calculate LDL-C but remains most common
  • Hopkins-Martin or NIH are the preferred equations
  • If LDL-C not being calculated using above, ask your lab to change
• Less accurate if TGs > 150 mg/dL
  • The higher the TGs, the worse LDL-C performs (discordance)
  • The more LDL-C is lowered (< 70 mg/dL), the less accurately it reflects LDL particles and ApoB

NonHDL-C: Often Superior to LDL-C

NonHDL-C (Total Cholesterol minus HDL-C) is as good or better than LDL-C.

• Recommended over LDL-C when TG high (> 150 mg/dL)
  • Despite this ancient guideline recommendation (ca. 2001), it is seldom followed in clinical practice
  • Reflects LDL-C + other atherogenic cholesterol, mainly VLDL-C
  • Despite recommendations, many labs don't list Non-HDL-C in report
  • If not listed, can be manually calculated (TC - HDL-C), but nobody likes to do math in a busy clinic
  • If your lab doesn't list NonHDL-C, request that they do — it's not hard
  • Comes "free" in standard lipid panel — but this isn't helpful if the lab doesn't list it, or the provider doesn't calculate it or know what it means
• No fasting required.
• So why do we continue to use LDL-C? Great question. Mostly because it's cheap, available, standardized (?), and let's face it — would probably cause mass hysteria if we replaced it overnight. It works pretty good. But we do have better tools. Only YOU can advocate for better.

HDL-C: Misconceptions and Cautions

HDL-C has never been a target or goal of therapy in any cholesterol guideline.

• HDL-C tells us nothing about the functionality of HDL particles. For example:
  • High HDL-C can be seen with dysfunctional HDL, where HDL cannot offload cholesterol and hence the concentration (mg/dL) goes up
  • Conversely, low HDL-C has been seen with highly efficient HDL, where HDL is so efficient at offloading cholesterol that the concentration is low
    • Apo A-1 Milano: Founder effect genetic variant with very low HDL-C and associated with higher lifespan
• Until an HDL functional assay is developed, HDL-C or HDL-P will not be particularly helpful in lipid management
• Stop saying "good cholesterol." It's misleading and dangerous.
  • Years (decades) of poor public health messaging on this topic has set us back. We're trying to undo this.
  • Giving out "points" for high HDL-C may underestimate risk
  • Women typically have higher HDL-C than men — another example of missing the mark in assessing CV risk in women
• Caveat: There may be value in seeing a low HDL-C on a lipid panel — it may alert the clinician to a problem — particularly the "atherogenic triad." But only if they are trained to look at TG and then observe or calculate the nonHDL-C discrepancy to LDL-C

See also: Too Much of a Good Thing — HDL.

Triglycerides (TGs): Context Matters

Triglycerides are not themselves known to be directly causal to atherosclerosis, though this continues to be investigated.

• If > 500 mg/dL (severe) the primary objective is to treat the TGs to avoid the risk of pancreatitis
  • Pancreatitis is much more likely with TG > 1000 mg/dL, but since TGs fluctuate considerably, a fasting level > 500 mg/dL is severe and warrants urgent attention
• If 150–499 mg/dL, look for and address associated comorbidities (DM and dysglycemia, obesity and visceral adiposity, metabolic syndrome, fatty liver disease)
• "Atherogenic triad": High TGs, low HDL-C, high sdLDL-P
  • Should alert you to the high likelihood of elevated ApoB and discordance to LDL-C (lower LDL-C may be misleading)
  • Underestimates risk

See also: Something Smells Fishy — Fish Oil.

TC/HDL-C Ratios: Obsolete and Misleading

Focus on LDL-C, nonHDL-C, and ApoB. That's all you really need. In fact, if you just focused on ApoB, you'd be doing great.

LDL-P: When to Use

LDL-P should reflect and be concordant with ApoB.

• In general, can be used in place of ApoB to account for discordance or inaccuracies with LDL-C (residual risk)
  • In our experience, LDL-P is not as well standardized as ApoB. We have observed not too infrequent cases of discordance between ApoB and LDL-P.
  • ApoB is preferred over LDL-P
  • ApoB/LDL-P discordance is a much more advanced and nuanced discussion with many gaps in knowledge. Use clinical judgment.
• If ApoB > LDL-P, treat ApoB
• If LDL-P > ApoB:
  • Look for other cardiometabolic comorbidities (DM and dysglycemia, high TG, fatty liver, obesity) and treat
  • It may be prudent to consider more aggressive treatment of LDL-P
  • If no other cardiometabolic features present, consider LDL-P a false positive

Small Dense LDL-P vs Large Buoyant LDL-P

"Size Doesn't Matter" — when it comes to LDL particles. They are all atherogenic.

• No convincing data exists demonstrating increased atherogenicity to small dense LDL-P, once total LDL-particle number is accounted for
• Measuring sub-particle fractions does not appear to provide additional clinical value apart from measuring ApoB, or total LDL-particle count
• Caveat: There may be some value in measuring advanced lipid subfractions in the individual with insulin resistance who has the "Pattern B" (old nomenclature for sdLDL-P) phenotype and is transitioning to a "Pattern A" (large buoyant LDL-P) through optimal treatment pathways and therefore providing some bit of "proof" of progress.

6. Treatment Goals in FH — Tiered Approach (2026 ACC/AHA/NLA)

The 2026 ACC/AHA/NLA Dyslipidemia Guidelines establish a tiered LDL-C goal system for FH based on clinical presentation:

Clinical Scenario	LDL-C Goal (2026)	ApoB Goal	Minimum Reduction
FH + Clinical ASCVD (Secondary Prevention)	< 55 mg/dL	< 65 mg/dL	≥ 50% from baseline
HeFH + Risk Factors (e.g., Lp(a), family Hx of early ASCVD)	< 70 mg/dL	< 80 mg/dL	≥ 50% from baseline
HeFH Without Additional Risk Factors	< 100 mg/dL	< 90 mg/dL	≥ 50% from baseline
Pediatric FH (HeFH), Age 9–11	< 100 mg/dL	—	≥ 50% from baseline
Pediatric HoFH	< 100 mg/dL (primary) < 70 mg/dL (with ASCVD)	—	≥ 50% from baseline

Key Guidelines:
2026 ACC/AHA/NLA Dyslipidemia Guidelines, Management Section

2026 NLA Expert Clinical Consensus on Familial Hypercholesterolemia, J Clin Lipidol

2026 NLA Update on Treatment Intensity: All FH patients irrespective of primary or secondary prevention should obtain at least a > 50% reduction from baseline LDL-C levels in addition to achieving specific LDL-C goals. Even FH patients who appear to be at "low risk" (e.g., young, CAC = 0, no other risk factors) should maintain long-term LDL-C goal < 70 mg/dL because their lifetime risk is high. Evidence supports that ASCVD event risk is proportional to achieved LDL-C down to 20 mg/dL or lower.

Key Trials Supporting Aggressive LDL-C Lowering:
FOURIER: Evolocumab in secondary prevention. NEJM. 2017.

ODYSSEY OUTCOMES: Alirocumab after acute coronary syndrome. NEJM. 2018.

VESALIUS-CV: Evolocumab in high-risk primary prevention. NEJM.

7. Therapeutic Options

Foundational Therapy

• Statins — First-line therapy; high-intensity statin regardless of 10-year risk if LDL-C ≥ 190 mg/dL (2018 ACC/AHA)
• Ezetimibe — Add if statins not sufficient; produces additional 18–25% LDL-C lowering; well tolerated

PCSK9 Inhibitors and Next-Generation Agents

Appropriate as second-line and third-line agents depending on response to statin + ezetimibe. Multiple modalities now available:

• Monoclonal antibodies (PCSK9):
  • Repatha (evolocumab) — FOURIER trial proven; ~60% LDL-C reduction
  • Praluent (alirocumab) — ODYSSEY OUTCOMES proven; ~58% LDL-C reduction
• Third-generation PCSK9 inhibitor (2025 approval):
  • Lerodalcibep — Recombinant fusion protein (albumin + adnectin); approved December 2025 for adults with hypercholesterolemia including HeFH; lowers LDL-C by 59–65% in HeFH
• siRNA PCSK9 silencer:
  • Inclisiran (Leqvio) — Gene-silencing technology; twice-yearly dosing; now included in 2026 ACC/AHA/NLA Dyslipidemia Guidelines algorithm as second-line PCSK9i option; CV outcomes trials (ORION-4, VICTORION-2P) ongoing
• Oral PCSK9 inhibitor (pipeline):
  • Enlicitide decanoate — Oral agent; lowered LDL-C by 58.2% in HeFH; FDA approval pending

Bempedoic Acid

• Oral ACL inhibitor; 180 mg daily (also available as combination with ezetimibe)
• ~21% LDL-C lowering as monotherapy; ~40% with ezetimibe combination
• CLEAR OUTCOMES trial demonstrated MACE reduction in statin-intolerant patients
• No physiological activity within myocytes — may be useful for patients with statin intolerance
• See also: Statin Apocalypse or Pleiotropic Nirvana

Therapies for HoFH (Homozygous FH)

2026 ACC/AHA/NLA Guideline Figure 8 — HoFH Algorithm: The 2026 guidelines establish a tiered approach for HoFH management:

• ANGPTL3 inhibitor (COR 2b):
  • EVKEEZA (evinacumab) — Monoclonal antibody targeting ANGPTL3. Works independently of the LDL receptor pathway — critical for HoFH patients with absent or severely dysfunctional LDLR. FDA approved 2021; additional trials (EVOKE-HoFH2) demonstrating CV outcomes benefit in 2024
  • Typical LDL-C lowering: 38–45% when added to statin-based regimen
• Lipoprotein Apheresis — COR 1 for HoFH (2026 guidelines). Mechanical removal of LDL and Lp(a); used as primary or adjunctive therapy in HoFH; typically performed weekly or biweekly
• Lomitapide (Juxtapid) — MTP inhibitor; approved for HoFH; inhibits apoB secretion; typically produces 40–50% LDL-C reduction

🦶 Foot Stomper

Evinacumab for HoFH works even when LDL receptors are absent. It blocks ANGPTL3, an entirely different pathway. For the rarest and most severe patients with essentially non-functional LDLR, this is a lifeline — providing meaningful LDL reduction when traditional PCSK9i therapies (which depend on residual LDLR function) may be insufficient.

Historical Agents

• Bile acid sequestrants (cholestyramine, colestipol, colesevelam) — Niche role; modest LDL-C reduction (10–27%); may be useful during pregnancy/breastfeeding and in FH patients with diabetes (additional ~0.5% A1C lowering)
• Niacin — No longer recommended as add-on therapy to statins based on AIM-HIGH and HPS2-THRIVE trial results

Genetic Testing Companies

Many offer testing at low cost to the patient, some for free:

• Ambry Genetics
• Invitae
• GENinCode
• GB HealthWatch

8. Provider Knowledge Gaps

Many primary care providers are unfamiliar with FH and unfamiliar with when to screen for lipid disorders.

Even when parents request screening for LDL-C and Lp(a) for their children, many providers inform patients it's "too early."

Even worse, many providers continue to rely on archaic and erroneous notions around "cholesterol ratios." See What's Your ApoB? A Practical Approach to Lipid Biomarkers.

Patients still report the following scenario after finally seeking out a lipid specialist: "I've always been told that although my LDL-C is really high, but so is my HDL-C, which makes my ratio ok and I don't need any treatment."

9. Misinformation and LDL Deniers

Social media and other internet sources are unfortunately littered with misinformation about the causality of LDL with ASCVD.

These "LDL Deniers," as some have referred to them, tend to have a strong passion for a "ketogenic lifestyle" and in defending the purported health benefits of such a lifestyle have dangerously made it their mission to "debunk" the causality of LDL to ASCVD. They fail to understand risk — both near-term and lifetime.

See The Straw That Breaks the Camel's Back — LMHR (Lean Mass Hyper Responder).

LDL causality is not controversial in cardiovascular medicine. Denying it is misinformation.

10. 2026 ACC/AHA/NLA Dyslipidemia Guidelines & NLA Consensus: Critical Updates

The 2026 ACC/AHA/NLA Dyslipidemia Guidelines (published November 2025) and the accompanying 2026 NLA Expert Clinical Consensus on Familial Hypercholesterolemia represent a watershed moment in FH recognition and management. Key highlights include:

Genetic Testing & Diagnosis (Class I Recommendations)

• Genetic testing now COR 1 (Class I) for possible, probable, or definite FH — upgraded from earlier recommendations
• Cascade screening COR 1: Systematic testing of first-degree relatives mandatory
• Pediatric screening COR 1: Universal lipid screening ages 9–11; consider statin therapy by age 10 in FH
• Severe hypercholesterolemia algorithm (Figure 7): LDL-C ≥ 190 → evaluate for FH → order genetic testing → initiate cascade screening

Risk Assessment & Treatment (Class III: Harm for Standard Calculators)

• Risk calculators COR 3: Harm: PCE and PREVENT equations contraindicated in FH — systematically underestimate risk 5–10 fold
• FH-specific risk scores recommended: Montreal-FH-SCORE, FH-Risk Score when risk stratification needed (though management-level decisions use clinical criteria, not calculator output)
• Tiered treatment goals: LDL-C < 100 mg/dL (HeFH without additional risk); < 70 mg/dL (HeFH + risk factors); < 55 mg/dL (FH + ASCVD)
• ≥ 50% LDL-C reduction mandatory from baseline for all FH regardless of risk tier

Therapeutic Landscape — New Agents & Updated Algorithms

• Inclisiran (Leqvio): Now included in 2026 algorithm as second-line PCSK9i; twice-yearly dosing; CV outcomes ongoing
• Lerodalcibep (Nexletol): Third-generation PCSK9i; approved December 2025; 59–65% LDL-C reduction in HeFH
• Evinacumab (EVKEEZA) COR 2b for HoFH: ANGPTL3 inhibitor; works independent of LDLR; critical for nullLDLR and defective LDLR variants
• Lipoprotein apheresis COR 1 for HoFH: Mechanical removal of LDL; first-line or adjunctive therapy
• Bempedoic acid integration: ACL inhibitor; ~21% LDL-C reduction; particularly useful for statin-intolerant patients

General Updates

• Prevalence: Global prevalence of HeFH approximately 1 in 311 (~0.32%); HoFH ~1 in 300,000
• Inheritance terminology: FH described as "autosomal semidominant" (not "codominant")
• ICD-10 codes (2025): E78.010 (HoFH), E78.011 (HeFH), E78.019 (FH unspecified)
• Imaging caveat: Absence of CAC should never delay treatment in FH — most plaque is uncalcified in early disease
• Health disparities highlighted: Unawareness and undertreatment disproportionately affect younger adults, men, racial/ethnic minorities, lower education, lower SES

Key Evidence:
2026 ACC/AHA/NLA Dyslipidemia Guidelines. J Am Coll Cardiol. Published November 2025.

Ahmad Z, Agarwala A, Cuchel M, et al. 2026 NLA Expert Clinical Consensus on Familial Hypercholesterolemia. J Clin Lipidol. 2026.

Watts GF, Gidding SS, Hegele RA, et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023.

11. Related CardioAdvocate Content

• What's Your ApoB? — A Practical Approach to Lipid Biomarkers
• The Atherogenic Triad — When LDL-C underestimates risk
• Little Napoleon Complex — Lp(a) — The "Double Whammy" when combined with FH
• A Picture Worth a Thousand Words — CAC — When to image (and when not to delay treatment)
• There's an App for That — Risk Calculators — Why calculators fail in FH
• Wear Red for Women — Women are disproportionately reassured rather than evaluated
• Statin Apocalypse or Pleiotropic Nirvana — Statin therapy and FH
• The Straw That Breaks the Camel's Back — LMHR — LDL Deniers and misinformation
• Too Much of a Good Thing — HDL — Why "good cholesterol" is misleading
• Follow the Leader — Lipid Guidelines — FH treatment targets across guidelines
• The Sweet Spot — Diabetes — Metabolic syndrome and atherogenic risk overlap
• Barking Up the Wrong Tree — MASLD/MASH — Fatty liver and metabolic overlap
• Something Smells Fishy — Fish Oil — EPA and triglyceride management
• Who Needs a Specialist? — When to refer to a lipid specialist
• Precious Cargo — Pregnancy — FH management during pregnancy

The Bottom Line

• FH is common (~1 in 311), genetic, and dangerous — yet routinely missed
• LDL-C is a signal, not a character flaw
• Standard risk calculators do not apply
• Early recognition and treatment saves lives
• With modern therapies, premature ASCVD is largely preventable
• Screen all first-degree family members — cascade screening is critical
• The 2026 NLA Consensus reinforces intensified treatment goals and newer therapeutic options

"FH isn't rare. Missing it is."

CardioAdvocate helps people understand what matters — and how to speak up about it.

Disclaimer: Content on CardioAdvocate.com is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. No physician–patient relationship is created by use of this site. Always consult a qualified healthcare professional for personal medical concerns.